4-aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis

Neurology

Volumn 72, Issue 12, 2009, Pages 1100-1101

  Badruddin, Aamir ^a   Menon, Ravi S ^a   Reder, Anthony T ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BRAIN TOXICITY; CARDIOTOXICITY; CASE REPORT; CLINICAL FEATURE; COGNITIVE DEFECT; DIFFERENTIAL DIAGNOSIS; DRUG INTOXICATION; DRUG OVERDOSE; HUMAN; MALE; MYOPATHY; NEUROLOGIC EXAMINATION; PARANEOPLASTIC NEUROPATHY; PRIORITY JOURNAL;

EID: 67650381928     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000345063.17185.13     Document Type: Article

References (7)

1. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27:186-192.
2. Johnson NC, Morgan MW. An unusual case of 4-aminopyridine toxicity. J Emerg Med 2006;30: 175-177.
3. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127:701-712.
4. Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006;111: 224-259.
5. Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001;50:73-78.
6. Liguori R, Vincent A, Clover L, et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001;124:2417-2426.
7. Cochran SM, Harvey AL, Pratt JA. Regionally selective alterations in local cerebral glucose utilization evoked by charybdotoxin, a blocker of central voltage-activated K- channels. Eur J Neurosci 2001;14:1455-1463.